Skip to main content

Table 1 Relationship between IMPDH2 expression level and clinical pathological parameters of CRC

From: IMPDH2 promotes colorectal cancer progression through activation of the PI3K/AKT/mTOR and PI3K/AKT/FOXO1 signaling pathways

IMPDH2 expression
Characteristics n = 214 Low (%) High (%) P value x2
Gender     0.083 3.014
 Male 136 60(44.1) 76(55.9)   
 Female 78 25(32.1) 53(67.9)
Age (years)     0.154 2.033
 <55 106 37(34.9) 69(65.1)   
 ≥ 55 108 48(44.4) 60(55.6)
Tumor site     0.626 0.936
 Proximal colon 47 17(36.2) 30(63.8)   
 Distal colon 37 13(35.1) 24(64.9)
 Rectum 130 55(42.3) 75(57.7)   
Tumor size (cm)     0.253 1.305
 <5 116 42(36.2) 74(63.8)   
 ≥ 5 98 43(43.9) 55(56.1)
Tumor differentiation     0.758 0.554
 Well 81 34(42.0) 47(58.0)   
 Moderate 101 40(39.6) 61(60.4)
 Poor 32 11(34.4) 21(65.6)
T stage     0.048 6.057
 T1–2 59 31(52.5) 28(47.5)   
 T3 140 50(35.7) 90(64.3)
 T4 15 4(26.7) 11(73.3)
Lymph node state     < 0.001 13.525
 Positive 88 22(25.0) 66(75.0)   
 Negative 126 63(50.0) 63(50.0)
Distant metastasis     0.026 4.962
 Positive 38 9(23.7) 29(76.3)   
 Negative 176 76(43.2) 100(56.8)
Lymphovascular invasion     0.018 5.551
 Positive 73 21(28.8) 52(71.2)   
 Negative 141 64(45.4) 77(54.6)
Clinical stage     0.001 15.697
 1 53 29(54.7) 24(45.3)   
 2 63 31(49.2) 32(50.8)   
 3 60 16(26.7) 44(73.3)
 4 38 9(23.7) 29(76.3)